person · Reporting owner

Melincoff Gwen A

Disclosed activity across 6 companies

Tapewire entity: 2672
SEC CIK: 0001614890

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
COLLEGIUM PHARMACEUTICAL, INCCOLL · Entity 5169	Director	May 16, 2024	May 16, 2024
Chemomab Therapeutics Ltd.CMMB · Entity 7653	Director	June 01, 2026	June 03, 2026
Gain Therapeutics, Inc.GANX · Entity 6943	Director	July 15, 2026	July 17, 2026
Protalix BioTherapeutics, Inc.PLX · Entity 2671	Director	September 03, 2026	September 04, 2026
SOLENO THERAPEUTICS INCSLNO · Entity 46432	Director	May 25, 2023	May 26, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

COLLEGIUM PHARMACEUTICAL, INC

Report date May 16, 2024 · Filed May 16, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	52,468	Reported balance After 2024-05-16 transaction · row 1 1 source row Row 1 · 2024-05-16 · Grant · Acquired 7,693 · Balance 52,468 F1: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on May 16, 2025, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on May 16, 2025, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.

Chemomab Therapeutics Ltd.

Report date June 01, 2026 · Filed June 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock option (right to buy American Depositary Shares)SEC Table II · derivative / convertible security · Conversion / exercise price $1.86 · Expires 2036-06-01	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-06-01 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F1: The option reported in this row was granted to the Reporting Person by the Issuer on June 1, 2026 and vests and becomes exercisable in equal monthly installments over a 36-month period, commencing on June 1, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: The option reported in this row was granted to the Reporting Person by the Issuer on June 1, 2026 and vests and becomes exercisable in equal monthly installments over a 36-month period, commencing on June 1, 2026.

Gain Therapeutics, Inc.

Report date July 15, 2026 · Filed July 17, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.68 · Expires 2036-07-15	Direct	25,000	Reported balance After 2026-07-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-07-15 · Grant · Acquired 25,000 · Balance 25,000 F1: The option vests in 12 equal monthly installments commencing on July 24, 2026, subject to the Reporting Person's continuous service through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests in 12 equal monthly installments commencing on July 24, 2026, subject to the Reporting Person's continuous service through the applicable vesting date.

Protalix BioTherapeutics, Inc.

Report date September 03, 2026 · Filed September 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.59 · Expires 2036-09-03	Direct	17,000	Reported balance After 2026-09-03 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-09-03 · Grant · Acquired 17,000 · Balance 17,000 F1: The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant. F2: Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032, (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033 and (iv) options to purchase 15,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	8,500	Reported balance After 2026-09-03 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-09-03 · Grant · Acquired 8,500 · Balance 8,500 F3: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock. F4: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant.

F2: Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032, (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033 and (iv) options to purchase 15,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035.

F3: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock.

F4: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.

SOLENO THERAPEUTICS INC

Report date May 25, 2023 · Filed May 26, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.03 · Expires 2033-05-25	Direct	2,666	Reported balance After 2023-05-25 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-05-25 · Grant · Acquired 2,666 · Balance 2,666 F1: The shares subject to the Option shall vest on the earlier of the twelve-month anniversary of May 25, 2023 or the day before the next annual stockholder meeting, subject to the Reporting Person continuing to be a Service Provider through such date.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.25 · Expires 2033-05-26	Direct	10,000	Reported balance After 2023-05-26 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-05-26 · Grant · Acquired 10,000 · Balance 10,000 F2: The shares subject to the Option shall vest on November 26, 2023, subject to the Reporting Person continuing to be a Service Provider through such date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the Option shall vest on the earlier of the twelve-month anniversary of May 25, 2023 or the day before the next annual stockholder meeting, subject to the Reporting Person continuing to be a Service Provider through such date.

F2: The shares subject to the Option shall vest on November 26, 2023, subject to the Reporting Person continuing to be a Service Provider through such date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Tobira Therapeutics, Inc.

Report date November 01, 2016 · Filed November 03, 2016

Section 16 reporting ended · disclosed 2016-11-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.13 · Expires 2024-06-08	Direct	Reported balance After 2016-11-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2016-11-01 · Disposition to issuer · Disposed 13,539 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F4: The Shares subject to this option were fully vested immediately prior to the Effective Time.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.52 · Expires 2025-07-08	Direct	Reported balance After 2016-11-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2016-11-01 · Disposition to issuer · Disposed 15,500 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F4: The Shares subject to this option were fully vested immediately prior to the Effective Time.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.91 · Expires 2026-01-12	Direct	Reported balance After 2016-11-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2016-11-01 · Disposition to issuer · Disposed 17,778 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F4: The Shares subject to this option were fully vested immediately prior to the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time")

F2: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"),

F3: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor.

F4: The Shares subject to this option were fully vested immediately prior to the Effective Time.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 03, 2026 Filed Sep 4, 2026 10:00 UTC	Protalix BioTherapeutics, Inc. PLX · Entity 2671	GrantRestricted Stock Units · Derivative	8,500	$0.00	$0.00	Disclosure SEC source: 0001614890-26-000002 · form4-09042026_060915.xml · derivative · entry 2 Melincoff Gwen A · CIK 0001614890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock. F4 · derivative.exercise_date: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant. F4 · derivative.expiration_date: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant. Read SEC document
September 03, 2026 Filed Sep 4, 2026 10:00 UTC	Protalix BioTherapeutics, Inc. PLX · Entity 2671	GrantStock Options (Right to Buy) · Derivative	17,000	$0.00 Strike: $2.59	$0.00	Disclosure SEC source: 0001614890-26-000002 · form4-09042026_060915.xml · derivative · entry 1 Melincoff Gwen A · CIK 0001614890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2036-09-03 F1 · derivative.exercise_date: The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant. F2 · balance_after: Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032, (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033 and (iv) options to purchase 15,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035. Read SEC document
July 15, 2026 Filed Jul 17, 2026 12:31 UTC	Gain Therapeutics, Inc. GANX · Entity 6943	GrantStock Option (right to buy) · Derivative	25,000	$0.00 Strike: $1.68	$0.00	Disclosure SEC source: 0001104659-26-084435 · tm2620629-3_4seq1.xml · derivative · entry 1 Melincoff Gwen A · CIK 0001614890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2036-07-15 F1 · derivative.exercise_date: The option vests in 12 equal monthly installments commencing on July 24, 2026, subject to the Reporting Person's continuous service through the applicable vesting date. Read SEC document
September 03, 2025 Filed Sep 4, 2025 21:00 UTC	Protalix BioTherapeutics, Inc. PLX · Entity 2671	GrantStock Options (Right to Buy) · Derivative	15,000	$0.00 Strike: $1.64	$0.00	Disclosure SEC source: 0001415889-25-023706 · form4-09042025_050913.xml · derivative · entry 2 Melincoff Gwen A · CIK 0001614890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-09-03 F3 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. F4 · balance_after: Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032 and (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033. Read SEC document
September 03, 2025 Filed Sep 4, 2025 21:00 UTC	Protalix BioTherapeutics, Inc. PLX · Entity 2671	GrantCommon Stock	7,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-25-023706 · form4-09042025_050913.xml · nonDerivative · entry 1 Melincoff Gwen A · CIK 0001614890 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 7,500 F1 · price: Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the "Plan"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant. F2 · ownership.nature: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under the Plan must be registered in the name of a trustee. Read SEC document
June 24, 2025 Filed Jun 25, 2025 21:30 UTC	Gain Therapeutics, Inc. GANX · Entity 6943	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $1.79	$0.00	Disclosure SEC source: 0001641172-25-016538 · ownership.xml · derivative · entry 1 Melincoff Gwen A · CIK 0001614890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-06-24 F1 · derivative.exercise_date: The option vests in 12 equal monthly installments commencing on July 24, 2025, subject to the Reporting Person's continuous service through the applicable vesting date. Read SEC document
June 24, 2024 Filed Jun 27, 2024 01:30 UTC	Gain Therapeutics, Inc. GANX · Entity 6943	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $1.29	$0.00	Disclosure SEC source: 0001493152-24-025341 · ownership.xml · derivative · entry 1 Melincoff Gwen A · CIK 0001614890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2034-06-24 F1 · derivative.exercise_date: The option vests in 12 equal monthly installments commencing on July 24, 2024, subject to the Reporting Person's continuous service through the applicable vesting date. Read SEC document
May 16, 2024 Filed May 16, 2024 23:23 UTC	COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169	GrantCommon Stock	7,693	$0.00	$0.00	Disclosure SEC source: 0001062993-24-010542 · form4.xml · nonDerivative · entry 1 Melincoff Gwen A · CIK 0001614890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,468 F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on May 16, 2025, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock. Read SEC document
September 29, 2023 Filed Oct 3, 2023 21:00 UTC	Protalix BioTherapeutics, Inc. PLX · Entity 2671	GrantStock Options (Right to Buy) · Derivative	61,676	$0.00 Strike: $1.66	$0.00	Disclosure SEC source: 0001415889-23-013902 · form4-10032023_051032.xml · derivative · entry 1 Melincoff Gwen A · CIK 0001614890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,676 Underlying: Common Stock · 61,676 shares Expires 2033-09-29 F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended. F2 · balance_after: Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030 and (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032. Read SEC document
June 23, 2023 Filed Jun 26, 2023 20:38 UTC	Gain Therapeutics, Inc. GANX · Entity 6943	GrantStock Option (right to buy) · Derivative	10,500	$0.00 Strike: $4.50	$0.00	Disclosure SEC source: 0001209191-23-039721 · doc4.xml · derivative · entry 1 Melincoff Gwen A · CIK 0001614890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2033-06-23 F1 · derivative.exercise_date: The option vests in 12 equal monthly installments commencing on July 23, 2023, subject to the Reporting Person's continuous service through the applicable vesting date. Read SEC document
May 26, 2023 Filed May 26, 2023 22:30 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	GrantStock option (right to buy) · Derivative	10,000	$0.00 Strike: $5.25	$0.00	Disclosure SEC source: 0001209191-23-032696 · doc4.xml · derivative · entry 2 Melincoff Gwen A · CIK 0001614890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-05-26 F2 · derivative.exercise_date: The shares subject to the Option shall vest on November 26, 2023, subject to the Reporting Person continuing to be a Service Provider through such date. Read SEC document
May 25, 2023 Filed May 26, 2023 22:30 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	GrantStock option (right to buy) · Derivative	2,666	$0.00 Strike: $5.03	$0.00	Disclosure SEC source: 0001209191-23-032696 · doc4.xml · derivative · entry 1 Melincoff Gwen A · CIK 0001614890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,666 Underlying: Common Stock · 2,666 shares Expires 2033-05-25 F1 · derivative.exercise_date: The shares subject to the Option shall vest on the earlier of the twelve-month anniversary of May 25, 2023 or the day before the next annual stockholder meeting, subject to the Reporting Person continuing to be a Service Provider through such date. Read SEC document
May 18, 2023 Filed May 19, 2023 20:38 UTC	COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169	GrantCommon Stock	9,792	$0.00	$0.00	Disclosure SEC source: 0001062993-23-011815 · form4.xml · nonDerivative · entry 1 Melincoff Gwen A · CIK 0001614890 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,775 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 18, 2024, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock. Read SEC document
September 20, 2022 Filed Sep 22, 2022 20:09 UTC	Gain Therapeutics, Inc. GANX · Entity 6943	GrantStock Option (right to buy) · Derivative	10,500	$0.00 Strike: $3.50	$0.00	Disclosure SEC source: 0001209191-22-051009 · doc4.xml · derivative · entry 1 Melincoff Gwen A · CIK 0001614890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2032-09-20 F1 · derivative.exercise_date: The option vests fully on the day before the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service as a director of the Issuer. Read SEC document
September 07, 2022 Filed Sep 9, 2022 21:01 UTC	Protalix BioTherapeutics, Inc. PLX · Entity 2671	GrantStock Options (Right to Buy) · Derivative	50,000	$0.00 Strike: $1.03	$0.00	Disclosure SEC source: 0001104659-22-098944 · tm2225460-2_4seq1.xml · derivative · entry 1 Melincoff Gwen A · CIK 0001614890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-09-07 F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended. F2 · balance_after: Does not include options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030. Read SEC document
June 01, 2022 Filed Oct 14, 2022 22:30 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	GrantStock option (right to buy) · Derivative	2,666	$0.00 Strike: $2.55	$0.00	Disclosure SEC source: 0001209191-22-053697 · doc4.xml · derivative · entry 1 Melincoff Gwen A · CIK 0001614890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,666 Underlying: Common Stock · 2,666 shares Expires 2032-06-01 F1 · derivative.exercise_price: The per share exercise price and number of shares subject to the option reflect the 1-for-15 reverse stock split effected August 26, 2022. F1 · shares: The per share exercise price and number of shares subject to the option reflect the 1-for-15 reverse stock split effected August 26, 2022. F2 · derivative.exercise_date: The shares subject to the Option shall vest on the earlier of the twelve-month anniversary of June 1, 2022 or the day before the next annual stockholder meeting, subject to Reporting Person continuing to be a Service Provider through each such date. F1 · derivative.underlying_shares: The per share exercise price and number of shares subject to the option reflect the 1-for-15 reverse stock split effected August 26, 2022. F1 · balance_after: The per share exercise price and number of shares subject to the option reflect the 1-for-15 reverse stock split effected August 26, 2022. Read SEC document
May 19, 2022 Filed May 23, 2022 21:42 UTC	COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169	GrantCommon Stock	14,035	$0.00	$0.00	Disclosure SEC source: 0001062993-22-013313 · form4.xml · nonDerivative · entry 1 Melincoff Gwen A · CIK 0001614890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,983 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 19, 2023, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock. Read SEC document
June 01, 2021 Filed Jun 4, 2021 20:31 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	GrantEmployee stock option (right to buy) · Derivative	31,862	$0.00 Strike: $1.02	$0.00	Disclosure SEC source: 0000899243-21-022052 · doc4.xml · derivative · entry 1 Melincoff Gwen A · CIK 0001614890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,862 Underlying: Common Stock · 31,862 shares Expires 2021-06-01 F1 · derivative.exercise_date: The shares subject to the Option shall vest on the earlier of the twelve-month anniversary of June 1, 2022 or the day before the next annual stockholder meeting, subject to Reporting Person continuing to be a Service Provider through each such date. Read SEC document
May 20, 2021 Filed May 24, 2021 21:16 UTC	COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169	GrantCommon Stock	9,941	$0.00	$0.00	Disclosure SEC source: 0001192482-21-000454 · edgar.xml · nonDerivative · entry 1 Melincoff Gwen A · CIK 0001614890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,948 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 20, 2022, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock. Read SEC document
January 08, 2021 Filed Jan 13, 2021 02:20 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	GrantEmployee stock option (right to buy) · Derivative	40,000	$0.00 Strike: $2.24	$0.00	Disclosure SEC source: 0000899243-21-001699 · doc4.xml · derivative · entry 1 Melincoff Gwen A · CIK 0001614890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,887 Underlying: Common Stock · 40,000 shares Expires 2031-01-08 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the Option shall be deemed vested on the Transaction Date (which is January 8, 2021). Read SEC document
May 20, 2020 Filed May 22, 2020 20:21 UTC	COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169	GrantStock Option (Right to Purchase) · Derivative	8,095	$0.00 Strike: $22.05	$0.00	Disclosure SEC source: 0001192482-20-000362 · edgar.xml · derivative · entry 2 Melincoff Gwen A · CIK 0001614890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,095 Underlying: Common Stock · 8,095 shares Expires 2030-05-20 F2 · derivative.exercise_date: The option vests and becomes exercisable on May 20, 2021, subject to the director's continued service with the issuer. Read SEC document
May 20, 2020 Filed May 22, 2020 20:21 UTC	COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169	GrantCommon Stock	4,047	$0.00	$0.00	Disclosure SEC source: 0001192482-20-000362 · edgar.xml · nonDerivative · entry 1 Melincoff Gwen A · CIK 0001614890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,007 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 20, 2021, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock. Read SEC document
May 18, 2020 Filed May 20, 2020 21:56 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	GrantEmployee stock option (right to buy) · Derivative	9,530	$0.00 Strike: $3.41	$0.00	Disclosure SEC source: 0000899243-20-013725 · doc4.xml · derivative · entry 1 Melincoff Gwen A · CIK 0001614890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,530 Underlying: Common Stock · 9,530 shares Expires 2030-05-18 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the Option shall vest on the one year anniversary of the Transaction Date (which is May 18, 2020) or the day before the 2020 Annual Shareholder Meeting, whichever is earlier. Read SEC document
January 20, 2020 Filed Jan 22, 2020 22:01 UTC	Protalix BioTherapeutics, Inc. PLX · Entity 2671	GrantStock Options (Right to Buy) · Derivative	40,000	$0.00 Strike: $3.55	$0.00	Disclosure SEC source: 0001104659-20-005965 · tm205452-1_4.xml · derivative · entry 1 Melincoff Gwen A · CIK 0001614890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-01-20 F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended. Read SEC document
November 19, 2019 Filed Nov 20, 2019 22:02 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	PurchaseCommon Stock	10,000	$1.54	$15,364.00	Disclosure SEC source: 0000899243-19-027705 · doc4.xml · nonDerivative · entry 1 Melincoff Gwen A · CIK 0001614890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: This transaction was executed in multiple trades at prices ranging from $1.5299 to $1.54. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 10, 2019 Filed Jun 12, 2019 21:37 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	GrantEmployee stock option (right to buy) · Derivative	13,000	$0.00 Strike: $2.50	$0.00	Disclosure SEC source: 0000899243-19-016668 · doc4.xml · derivative · entry 1 Melincoff Gwen A · CIK 0001614890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2029-06-10 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the Option shall vest on the one year anniversary of the Transaction Date (which is June 10, 2019) or the day before the 2019 Annual Shareholder Meeting, whichever is earlier. Read SEC document
April 26, 2019 Filed Apr 29, 2019 15:22 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	GrantStock Option (Right to buy) · Derivative	20,000	$0.00 Strike: $1.98	$0.00	Disclosure SEC source: 0001209191-19-026336 · doc4.xml · derivative · entry 1 Melincoff Gwen A · CIK 0001614890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-04-26 F1 · derivative.exercise_date: The option vests as to 1/48th of the shares on May 26, 2019 and each one-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
April 25, 2019 Filed Apr 29, 2019 22:39 UTC	COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169	GrantStock Option (Right to Purchase) · Derivative	9,414	$0.00 Strike: $14.57	$0.00	Disclosure SEC source: 0001192482-19-000209 · edgar.xml · derivative · entry 2 Melincoff Gwen A · CIK 0001614890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,414 Underlying: Common Stock · 9,414 shares Expires 2029-04-25 F2 · derivative.exercise_date: The option vests and becomes exercisable on April 25, 2020, subject to the director's continued service with the issuer. Read SEC document
April 25, 2019 Filed Apr 29, 2019 22:39 UTC	COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169	GrantCommon Stock	4,707	$0.00	$0.00	Disclosure SEC source: 0001192482-19-000209 · edgar.xml · nonDerivative · entry 1 Melincoff Gwen A · CIK 0001614890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,960 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on April 25, 2020, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock. Read SEC document
May 24, 2018 Filed May 29, 2018 21:06 UTC	COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169	GrantStock Option (Right to Purchase) · Derivative	4,506	$0.00 Strike: $24.95	$0.00	Disclosure SEC source: 0001192482-18-000254 · edgar.xml · derivative · entry 2 Melincoff Gwen A · CIK 0001614890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,506 Underlying: Common Stock · 4,506 shares Expires 2028-05-24 F2 · derivative.exercise_date: The option vests and becomes exercisable on May 24, 2019, subject to the director's continued service with the issuer. Read SEC document
May 24, 2018 Filed May 29, 2018 21:06 UTC	COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169	GrantCommon Stock	2,253	$0.00	$0.00	Disclosure SEC source: 0001192482-18-000254 · edgar.xml · nonDerivative · entry 1 Melincoff Gwen A · CIK 0001614890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,253 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 24, 2019, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date in shares of the issuer's common stock. Read SEC document
August 09, 2017 Filed Aug 11, 2017 21:37 UTC	COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169	GrantStock Option (Right to Purchase) · Derivative	25,067	$0.00 Strike: $9.89	$0.00	Disclosure SEC source: 0001192482-17-000227 · edgar.xml · derivative · entry 1 Melincoff Gwen A · CIK 0001614890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,067 Underlying: Common Stock · 25,067 shares Expires 2027-08-09 F1 · derivative.exercise_date: The option vests and becomes exercisable on August 9, 2018, subject to the director's continued service with the issuer. Read SEC document
November 01, 2016 Filed Nov 3, 2016 14:35 UTC	Tobira Therapeutics, Inc. TBRA · Entity 181299	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	17,778	Not disclosed Strike: $7.91	Not disclosed	Disclosure SEC source: 0001209191-16-148110 · doc4.xml · derivative · entry 3 Melincoff Gwen A · CIK 0001614890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,778 shares Expires 2026-01-12 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2 · price: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3 · price: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2 · derivative.exercise_date: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3 · derivative.exercise_date: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F4 · derivative.exercise_date: The Shares subject to this option were fully vested immediately prior to the Effective Time. Read SEC document
November 01, 2016 Filed Nov 3, 2016 14:35 UTC	Tobira Therapeutics, Inc. TBRA · Entity 181299	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	15,500	Not disclosed Strike: $16.52	Not disclosed	Disclosure SEC source: 0001209191-16-148110 · doc4.xml · derivative · entry 2 Melincoff Gwen A · CIK 0001614890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,500 shares Expires 2025-07-08 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2 · price: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3 · price: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2 · derivative.exercise_date: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3 · derivative.exercise_date: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F4 · derivative.exercise_date: The Shares subject to this option were fully vested immediately prior to the Effective Time. Read SEC document
November 01, 2016 Filed Nov 3, 2016 14:35 UTC	Tobira Therapeutics, Inc. TBRA · Entity 181299	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	13,539	Not disclosed Strike: $8.13	Not disclosed	Disclosure SEC source: 0001209191-16-148110 · doc4.xml · derivative · entry 1 Melincoff Gwen A · CIK 0001614890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,539 shares Expires 2024-06-08 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2 · price: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3 · price: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2 · derivative.exercise_date: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3 · derivative.exercise_date: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F4 · derivative.exercise_date: The Shares subject to this option were fully vested immediately prior to the Effective Time. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.